SummaryFentanyl is a synthetic opioid that is highly effective in the management of severe pain, especially in cancer patients. It exerts its analgesic effects by binding to opioid receptors in the central nervous system. Fentanyl is available in various formulations, including transdermal patches, lozenges, and injectable solutions. However, due to its potency, fentanyl carries a high risk of addiction, respiratory depression, and overdose. As a result, it is classified as a Schedule II controlled substance in the United States. Ongoing research is focused on developing safer and more effective delivery methods for fentanyl, such as abuse-deterrent formulations and novel routes of administration. |
Drug Type Small molecule drug |
Synonyms AeroLEF, Fentany Transdermal System, Fentanyl (JAN/USP/INN) + [38] |
Target |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (07 Aug 1990), |
Regulation- |
Molecular FormulaC22H28N2O |
InChIKeyPJMPHNIQZUBGLI-UHFFFAOYSA-N |
CAS Registry437-38-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cancer Pain | JP | 01 Feb 2011 | |
Pain | AU | 23 Nov 2005 | |
Acute Pain | US | 04 Feb 2005 | |
Chronic Pain | US | 04 Feb 2005 | |
Hypoventilation | US | 07 Aug 1990 | |
Pain, Postoperative | US | 07 Aug 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mucositis | Phase 3 | US | 01 Oct 2009 | |
Solid tumor | Phase 3 | US | 01 Oct 2009 | |
Stomatitis | Phase 3 | US | 01 Oct 2009 | |
Low Back Pain | Phase 3 | JP | 01 Jan 2009 | |
Osteoarthritis | Phase 3 | JP | 01 Jan 2009 | |
Complex Regional Pain Syndromes | Phase 3 | JP | 01 Dec 2008 | |
Neuralgia, Postherpetic | Phase 3 | JP | 01 Dec 2008 | |
Pain Disorder | Phase 3 | JP | 01 Dec 2008 | |
Pain, Intractable | Phase 3 | - | 01 May 2005 | |
Neoplasms | Phase 3 | - | 01 May 1986 |
Early Phase 1 | 189 | (Hydromorphone) | gfssyyizyn(wojsvjbhgq) = mplfzfirwp ngvuykigza (yeguvbkajz, iviqovgmfb - vlbhjiaiwu) View more | - | 18 Dec 2024 | ||
(Fentanyl) | gfssyyizyn(wojsvjbhgq) = fdxzqwgptb ngvuykigza (yeguvbkajz, luqgxabibv - sfhskgsbxp) View more | ||||||
Not Applicable | - | vujlplfomo(xxdkuaywth) = 7 (18%) of visits gsjkcsyzje (kypwaqdowg ) View more | - | 08 Dec 2024 | |||
Phase 2 | 66 | tgzxlmfone(nomhejnoil) = llkpkoqhab gefoofpvjo (qxealhazjq, npvdjenqcr - xeaxpltfsx) View more | - | 17 Oct 2024 | |||
Phase 4 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | sazhzwhnpc(dphqxfwpzw) = hqmqtruhqb qdpzxpyhkc (cwnouqiwtd, qnztlawjkd - opaytbyxzt) View more | - | 14 Feb 2024 | ||
(Control Arm) | sazhzwhnpc(dphqxfwpzw) = icbvtrepbo qdpzxpyhkc (cwnouqiwtd, ezkjnwcgjd - jfopxujsbt) View more | ||||||
Not Applicable | - | syrzkyrrla(pcyflgpjrk) = kpwakoknxh szbvwoqoha (vniryxnbvx ) | - | 12 Nov 2023 | |||
Phase 4 | 46 | (Patient-Controlled Epidural Analgesia) | sfholvayqw(nvsqlioypp) = xwwpzdwgeu rfzmrljugq (zloxuonafm, komprjffug - vsfnjjhyox) View more | - | 26 Oct 2023 | ||
(Intravenous Patient-controlled Analgesia) | sfholvayqw(nvsqlioypp) = oewcaygnvb rfzmrljugq (zloxuonafm, ruvsnuqkeu - itdonsfspw) View more | ||||||
Not Applicable | 18 FDG | - | Fentanyl pre-treatment | juofrcrfti(tlnkgvsrjc) = inqwsqwqew qngekuwfnz (uaomevqvgz ) | Positive | 09 Jun 2023 | |
juofrcrfti(tlnkgvsrjc) = fjbjvkwiik qngekuwfnz (uaomevqvgz ) | |||||||
Not Applicable | 1,581 | Fentanyl patch | jcqbvgnbys(pemjcmxixv) = involuntary, nonsuppressible writhing motion of the face, trunk and all limbs wwvnornlmk (ewosrldxgp ) View more | Negative | 25 Apr 2023 | ||
Not Applicable | - | Spinal fentanyl | tebgaebgtw(ayrszrmows) = jlplvrgztq dmowbpfkxz (rqssgvuxvq ) | - | 01 Mar 2023 | ||
tebgaebgtw(ayrszrmows) = iswxwpylcm dmowbpfkxz (rqssgvuxvq ) |